Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Aclarion, Inc. ( (ACON) ) has provided an announcement.
On January 30, 2025, Aclarion, Inc. announced a Securities Purchase Agreement to sell 506,803 shares of its common stock at $9.25 each in a registered direct offering, expected to raise approximately $4.7 million. The proceeds are intended for market development, clinical evidence, product development, and general corporate purposes. The offering, managed by Dawson James Securities, Inc., is anticipated to close around January 31, 2025, pending customary conditions.
More about Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and augmented intelligence algorithms. It focuses on the chronic low back pain market with its Nociscan platform, which assists physicians in identifying painful lumbar discs to optimize treatment strategies.
YTD Price Performance: -82.59%
Average Trading Volume: 169,236
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.11M
For detailed information about ACON stock, go to TipRanks’ Stock Analysis page.
